Preferences of patients and at risk individuals for preventive approaches to rheumatoid arthritis by Falahee, Marie et al.
 
 
University of Birmingham
Preferences of patients and at risk individuals for
preventive approaches to rheumatoid arthritis
Falahee, Marie; Finckh, Axel; Raza, Karim; Harrison, Mark
DOI:
10.1016/j.clinthera.2019.04.015
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Falahee, M, Finckh, A, Raza, K & Harrison, M 2019, 'Preferences of patients and at risk individuals for
preventive approaches to rheumatoid arthritis', Clinical Therapeutics, vol. 41, no. 7, pp. 1346-1354.
https://doi.org/10.1016/j.clinthera.2019.04.015
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 31/07/2019
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
Abstract (296 words): 
 
Effective treatments for rheumatoid arthritis (RA) are available and can lead to remission for some 
patients but most patients remain on potentially toxic and expensive medications in the long term. 
Interest is increasingly turning to the disease phases preceding the development of RA that 
represent opportunities for preventive interventions. ‘At risk’ target populations include individuals 
with genetic and environmental risk factors,  those who have developed systemic autoimmunity, 
and those who have developed clinically suspect symptoms (e.g. arthralgias without synovitis, or an 
early arthritis). 
Ongoing prospective studies will inform the development of increasingly accurate predictive tools to 
identify individuals at risk of developing RA. Furthermore a range of preventive approaches have 
been suggested, including lifestyle modification (e.g. smoking cessation) and pharmacological 
interventions (e.g. hydroxychloroquine, methotrexate, abatacept, rituximab) that are currently the 
subject of randomised controlled trials. 
As prediction and prevention of RA evolve, it is increasingly likely that those at risk (including 
asymptomatic individuals) may be faced with complex decisions about whether to accept 
assessment of their risk status or to take a preventive intervention associated with risk of serious 
adverse events and uncertain benefit. Acceptance of preventive medication in other contexts can be 
low. For example, less than 25% of women at high risk for breast cancer are willing to take 
preventive hormonal treatments. Actual uptake is lower still. 
Patients’ beliefs and preferences predict treatment uptake and adherence. Before the dream of 
preventing RA can become reality, healthcare providers need to understand the perspectives of 
individuals in the target population, to identify barriers and facilitators for this approach. This 
commentary will review what is currently known about the perspectives of patients and individuals 
at risk about predictive and preventive approaches for RA and identify gaps to be addressed to 
inform the development of efficient preventive strategies. 
  
Main text: (3032 words) 
 
Introduction 
 
Rheumatoid arthritis (RA) is a common chronic inflammatory disease affecting approximately 1% of 
the population. Painful swelling of the joints is typically accompanied by fatigue and depression, and 
without effective treatment RA can lead to joint destruction and deformity. A number of treatments 
are now available for patients with RA that can, in some cases, lead to disease remission1, but most 
patients have to remain on potentially toxic and often expensive medications in the long term.2 
Furthermore, many patients have persistent synovial inflammation despite current therapeutic 
approaches and some experience significant extra-articular complications of their RA, including 
cardiovascular disease and osteoporotic fractures. RA presents a significant burden not only to the 
individual and their families, but also to society through increased healthcare utilisation, disability 
and reduced ability to work.3, 4 Given this, interest is increasingly turning to the phases of disease 
leading up to the development of RA during which interventions may be put in place to reduce the 
risk of RA development5. Accurate identification of individuals at risk of developing RA and effective 
prevention would likely provide a highly cost-effective strategy for the management of this 
condition. 
European League Against Rheumatism (EULAR) recommendations for prospective studies identify 
distinct ‘at risk’ groups, each of which represents a potential opportunity for preventive 
intervention. Individuals without RA who are key target groups for preventive approaches may have 
one or more of the following: [1] genetic risk factors for RA; [2] environmental risk factors for RA; [3] 
systemic autoimmunity associated with RA (typically associated with the development of 
rheumatoid factor and/or anti-citrullinated protein/peptide antibodies in the blood); [4] 
musculoskeletal symptoms suggestive of underlying inflammation but  without clinically apparent 
synovial swelling (also known as clinically suspect arthralgias6); [5] an early arthritis that does not yet 
fulfil classification criteria for RA7.   
Predictive tools are currently available that can estimate the risk of RA development for patients in 
different at risk phases. For example, tools have been developed to predict RA development in 
patients with arthralgias and systemic autoimmunity8 and undifferentiated arthritis9. These rules 
include a range of clinical and laboratory variables including inflammatory markers and the levels of 
a range of RA related autoantibodies. Additional predictive variables have also been explored. In 
patients with arthralgias these include the interferon signature and B cell signatures 10-12 and 
ultrasound findings in the joints. 13 In patients with unclassified arthritis the presence of ultrasound 
defined subclinical synovitis and tenosynovitis have also been investigated 14, 15. Furthermore, tools 
are being developed to predict RA in individuals in earlier ‘at risk’ stages, for example in individuals 
with a family history of RA16.  Having identified individuals as being at risk of RA, a range of potential 
approaches may be available to reduce RA risk. These include lifestyle modification and 
pharmacological interventions 17. Of lifestyle modifications, smoking cessation18 is likely to be most 
beneficial but other environmental risk factors have been defined for RA including silica dust and air 
pollution which may also be amenable to environmental modification19. Amongst pharmacological 
interventions, the first to be assessed in the context of a clinical trial was intramuscular 
glucocorticoid,  which did not delay arthritis development in patients with autoantibody positive 
arthralgias, 20 but prevented 1 in 10 patients with very early inflammatory polyarthritis from 
progressing to RA and delayed prescription of disease modifying antirheumatic drugs (DMARDs)21.  A 
trial of rituximab in patients with autoantibody positive arthralgias and either imaging synovitis or 
evidence of an acute phase response on blood tests showed that a single infusion of the B cell 
depleting agent significant delayed the onset of arthritis – but did not reduce the number of patients 
who eventually developed arthritis22. However, the preventive effect of a number of additional 
drugs (e.g. hydroxychloroquine, atorvastatin, methotrexate, abatacept) is currently being assessed in 
randomised controlled trials. Further work is needed to define which lifestyle / pharmacological 
intervention is most effective in which at risk stage – with different stages likely to be amenable to 
different preventive approaches. 
 
 
Importance of understanding ‘patient’ preferences for preventive approaches  
 
Any preventive treatment will carry risks of adverse events without certainty of preventing the 
development of RA. Individuals at risk will need to understand their own risk of developing RA and 
be able to balance it against the risk of drug-related adverse events and the potential benefits of a 
preventive treatment. Communication of probabilities of risks and benefits is a complex task. 
Physicians can find it difficult to interpret and communicate risk effectively23 and patients struggle to 
accurately estimate and understand their own risks.24 The manner in which benefits and risks of 
treatment are presented to patients further influences health decisions.25 The most effective way of 
conveying risk information may differ according to the individuals’ characteristics, such as 
personality, education, literacy and numeracy.26  
Risk aversion to adverse events has been consistently found to influence the uptake of preventive 
medication,27-29 which can be amplified by a general distrust in medication.30 Effectiveness of 
treatment seems to have a more variable impact on decision making and depends on the specific 
context. Participants’ willingness to take treatment for cardiovascular prevention changed little with 
variations in treatment effectiveness.31 In order to take preventive therapy patients may actually 
require a higher benefit than the medication can achieve.32 Other attributes of preventive 
treatments, such as the method of administration may have an important impact on treatment 
acceptance. Patients evaluating preventive medication for osteoporosis deemed the route of 
administration to be as important as the likelihood of adverse events.33  
Acceptance of and adherence to preventive interventions for RA will be dependent not just on the 
treatment risks and benefits but also on patients’ beliefs and preferences. In the context of other 
diseases, acceptance of preventive medication is low. Fewer than 25% of women at high risk for 
breast cancer are willing to take preventive hormonal treatment. Effective uptake of medication is 
even lower28, and predicted by patients’ beliefs about medicine34. Acceptance of treatment for 
osteoporosis is somewhat higher, but still only about half of post-menopausal women would accept 
preventive medication at the recommended fracture risk threshold.35 
There is therefore an increasing need for formative research to be conducted in the potential target 
populations for preventive intervention, to identify the most important considerations in decision 
making about treatments, the weight given to various treatment characteristics and how these vary 
according to the clinical setting. The remainder of this commentary will review what is currently 
known about the perspectives of patients and individuals at risk about predictive and preventive 
approaches for RA, and identify knowledge gaps that could usefully be addressed to inform the 
development of ethical and efficient preventive strategies. 
 
 
Preferences for assessment of the risk of developing RA 
 
Effective risk stratification is an essential precursor to preventive approaches and an important 
consideration for proof-of-concept trials as preventive efficacy may be difficult to demonstrate in 
heterogeneous populations.36 Existing models to predict the development of RA in different ‘at risk’ 
groups have discriminative ability37, 38 though further evidence from prospective studies is needed to 
validate and improve risk prediction in pre-clinical disease stages.19, 39  
As prediction and prevention of RA evolve, individuals are increasingly likely to be provided with 
disease risk estimates, whether by healthcare professionals or via commercial providers (e.g. direct-
to-consumer genetic testing). Early evidence suggests that a web-based tool providing personalized 
RA risk education for first degree relatives of RA patients increases participants’ knowledge of RA 
risk factors, intentions to change risk related behaviours, and results in risk-reducing lifestyle 
changes.40, 41 However evidence of the impact of biomarker-based risk information on health 
behaviour change across disease areas is limited42, 43. Further research is needed to understand the 
extent to which inconsistent findings can be explained by heterogeneity in individuals’ responses to 
risk information.  
It is important that risk information is communicated in a tailored way that is sensitive to the needs 
and concerns of those affected44. Reviews of qualitative studies of stakeholder perceptions of 
predictive testing in other chronic diseases have highlighted challenging social and ethical issues 
associated with the provision of risk information, including concerns relating to information security 
and the potential for risk information to have a negative impact.45, 46 Qualitative studies of the 
symptoms experienced by patients with a diagnosis of clinically suspect arthralgia demonstrate that 
being ‘at risk’ of disease progression can have a considerable negative psychological impact47-49. On 
the other hand, a recent randomized controlled trial showed that personalized risk communication 
provided reassurance to first degree relatives of RA patients50. It is therefore essential to understand 
the perspectives of all those likely to be affected by predictive testing for RA, to identify support 
needs and address preferences for the communication of risk information. 
The first study to report on the perspectives of individuals at risk on predictive approaches for RA 
used qualitative interviews to explore the views of first-degree relatives of existing RA patients in 
three European countries.51 Participants described a lack of awareness about RA and risk factors for 
RA. Though participants appreciated the value of predictive approaches to facilitate early treatment 
and preventive intervention, concerns were raised about the accuracy of risk information and the 
potential for it to have a negative impact on future decision-making and the wellbeing of 
participants themselves and of other family members.  
Reliable access to first degree relatives is usually indirect and via existing patients with a diagnosis of 
RA. This in turn depends on patients’ willingness to pass on information to their relatives about RA 
risk. It is therefore important to understand patients’ perspectives in this context to identify barriers 
and facilitators to approaches targeting first-degree relatives. This was the focus of a UK based 
qualitative study52 which described selective and restricted family communication about RA and 
further emphasised a demand for informational resources about RA and risk factors for RA to 
support predictive approaches and communication amongst family members. Positive attitudes 
towards risk assessment for their relatives were associated with an expectation that the results 
would be able to rule in, or rule out RA. Negative viewpoints were associated with an appreciation of 
the probabilistic nature of risk information. 
A qualitative interview study of the perspectives of both asymptomatic and symptomatic (clinically 
suspect arthralgias without inflammatory arthritis) individuals who had received a positive test result 
for anti-citrullinated protein antibodies (ACPA), that was conducted across three European 
countries53, found that symptomatic individuals were more likely to describe feelings of anxiety in 
response to learning about their risk status, and were more receptive to further predictive tests, 
including tissue sampling. All participants described the need for tailored, accessible informational 
resources to support predictive and preventive strategies for RA. 
Taken together these qualitative studies highlight educational and psychological support needs for 
the provision of information about future development of RA. Positive viewpoints were associated 
with high perceived predictive accuracy and availability of highly effective preventive strategies. This 
aligns with findings from other chronic diseases.54, 55 Communication of the imprecision of 
probabilistic estimates has been shown to affect decision making about RA treatments56 and 
effective communication of the accuracy of prognostic models is an important challenge for 
predictive approaches57. 
 
 
Preferences for interventions to reduce risk of developing RA  
 
Several European qualitative studies have explored preferences relating to preventive interventions 
for RA of first-degree relatives58-60, RA patients52, 59, and ACPA positive individuals without arthritis.53  
Lifestyle change was preferred over pharmacological interventions to reduce RA risk52, 53, 58-60, 
however positive viewpoints were associated with the perspective that any intervention would need 
to substantially reduce or completely remove their risk of RA. Symptomatic individuals were more 
likely than asymptomatic individuals to consider preventive medications, subject to their efficacy 
and side-effect profile53. 
Some North American indigenous populations have a prevalence of RA estimated to be 5-7% higher 
than in the general population, and in some populations approximately 50% of patients have 
relatives with the disease61, 62. A qualitative study of 14 family members of RA patients in two First 
Nations (Cree and Oji-Cree Nations) in Manitoba suggested that a preventive approach with oral 
drug intervention with low toxicity, communicated appropriately, within the context of a research 
study led by a known and trusted researcher might be acceptable.63 However, discussions in that 
study suggested that lifestyle change, for example smoking cessation, was of limited interest.63 Fear 
of drug side effects was highlighted as a central theme, which has also been identified in qualitative 
studies in Europe58, 60. 
Further research has involved linked qualitative and quantitative studies to assess the preferences of 
at-risk populations for preventive treatments for RA. These approaches use qualitative studies to 
identify key aspects of decision-making, which are subsequently used to develop choice-based 
surveys to quantify preferences.  
The first study of this kind was based in Switzerland and included interviews with 20 first-degree 
relatives of RA patients. The findings showed that in addition to treatment effectiveness, treatment 
safety (few adverse effects preferred) and mode of administration (oral tablet taken infrequently at 
home preferred) are likely to be the key features of a preventive treatment.58 The choice-based 
(best-worst scaling) study derived from this qualitative work confirmed that preventive treatment 
would have to be targeted to those at high risk of developing RA and offer a high reduction in the 
risk of developing RA with a low-risk of serious side effects for prevention to be acceptable.64 
Overall, predicted uptake of  preventive intervention was low, and results suggested the avoidance 
of risks of side effects was key to prevention; some individuals would accept a 10% risk of serious 
side effects for a highly effective treatment, but most would prefer a moderately effective treatment 
with a very low risk of serious side effects.64  
A similar North American study sought perspectives from patients with RA, first-degree relatives of 
patients, and rheumatologists to understand what might influence preferences for preventive 
treatment strategies to inform the development of a choice-experiment. The key features identified 
related to the testing (who recommends the test, accuracy of predictive testing, an individual’s risk 
of developing RA) and the type of preventive treatment used (how a treatment is given, reduction in 
the risk of developing RA, risks and seriousness of side effects, strength of supporting evidence of 
risks and benefits, and other people’s opinions of the treatment). Patients and first-degree relatives 
described wanting to hear the evidence about preventive treatments from multiple trusted sources, 
including people with the disease and health care professionals.59 Preferences elicited from 
subsequent discrete choice experiments suggested that the decision to take preventive medication 
will depend primarily on factors other than the reduction in risk of RA.65, 66 For first-degree relatives 
of patients this is more likely to be how treatment is taken, the opinion of the health care 
professionals, and the potential risk and reversibility of side effects.65 Results from studies of 
patients and rheumatologists also emphasized the primary importance of the shared decision-
making process, with results indicating the opinion of the rheumatologist (for patients) and patient 
(for rheumatologists) as having the strongest influence on preferences.66 The results from these 
studies indicated that of the preventive pharmaceutical treatments currently being evaluated in 
randomized controlled trials, non-biologic DMARDs such as hydroxychloroquine and potentially 
methotrexate are much more likely to be acceptable preventive options than biologic DMARDs.65, 66  
 
Discussion and Conclusions 
 
This commentary has highlighted the importance of understanding the beliefs and preferences of 
the target population about predictive and preventive approaches to the management of RA and 
provided a narrative review of existing studies in this context. A range of qualitative studies have 
explored the perceptions of at risk groups on the quantification of an individual’s risk of developing 
RA and have highlighted important informational and support needs that should accompany risk 
assessment and the challenges of communicating risk effectively and ethically. Quantitative studies 
are now needed to assess and predict preference heterogeneity in relation to predictive testing and 
inform the development of tailored strategies. Studies of the perspectives of other stakeholders are 
also needed to provide a comprehensive understanding and assessment of feasibility and cost 
effectiveness. For example, it is important to address the perceptions of healthcare professionals in 
both primary and secondary care in this context, to understand the feasibility of implementing 
potentially complex prediction algorithms in routine clinical care. For the development and 
assessment of publically funded interventions it can also be argued that the preferences of members 
of the general public (tax-payers) should also be taken into account.67 Furthermore, genetic risk 
information relating to common multifactorial conditions is increasingly available to consumers 
outside of traditional healthcare settings. 
Both qualitative and quantitative studies have addressed the preferences of first-degree relatives in 
relation to preventive treatments for RA, and have shown that a range of treatment attributes 
impact on decision making, in addition to treatment effectiveness and risks. Further work is needed 
to identify effective predictors of preference heterogeneity. No quantitative studies have addressed 
the preferences of seropositive or symptomatic at risk individuals, despite the fact that these groups 
are perhaps the most likely candidates for most of the immunomodulatory agents that are currently 
being evaluated for prevention of RA. 
It is important to note that concerns about barriers to access to preventive services were not salient 
themes in the studies reviewed here. These studies were conducted in Canada and in European 
countries where there is universal healthcare, and the findings are unlikely to be representative of 
populations in, for example, insurance-based healthcare systems such as the United States of 
America where financial barriers to preventive interventions may be a key concern. Further work is 
needed to explore the impact of political and sociocultural context on perceptions of risk and 
preventive intervention. 
Decisions to take predictive tests or preventive treatments for RA are highly complex. For predictive 
testing to be worthwhile and RA prevention a reality, preventive interventions will need to offer a 
favourable benefit-harm trade-off whilst satisfying the preferences and needs of at risk individuals. 
Patients’ beliefs are strong predictors of adherence to treatments of RA,68, 69 and there is growing 
evidence that choice-based preference studies predict actual health behaviours.70, 71 Understanding 
the preferences of individuals at risk of RA and other stakeholders for prevention of RA is crucial to 
facilitate cost-effective clinical translation of investment in prevention research, and efficient and 
ethical recruitment of participants to preventive trials. The studies reviewed here are an important 
step towards achievement of these objectives. 
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